NEW YORK, NY / ACCESSWIRE / September 12, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Karyopharm Therapeutics Inc (NASDAQGS:KPTI)
Class Period: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline: September 23, 2019
The lawsuit alleges that Karyopharm Therapeutics Inc made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Learn about your recoverable losses in KPTI: http://www.kleinstocklaw.com/pslra-1/karyopharm-therapeutics-inc-loss-submission-form?id=3478&from=1
Eagle Bancorp, Inc. (NASDAQ:EGBN)
Class Period: March 2, 2015 to July 17, 2019
Lead Plaintiff Deadline: September 23, 2019
Eagle Bancorp, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in EGBN: http://www.kleinstocklaw.com/pslra-1/eagle-bancorp-inc-loss-submission-form?id=3478&from=1
Mallinckrodt Public Limited Company (NYSE:MNK)
Class Period: February 28, 2018 to July 16, 2019
Lead Plaintiff Deadline: September 24, 2019
The lawsuit alleges that Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in MNK: http://www.kleinstocklaw.com/pslra-1/mallinckrodt-public-limited-company-loss-submission-form?id=3478&from=1
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/559472/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-KPTI-EGBN-and-MNK
